Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Product Briefs: St. Jude TAVR Update; ADHD, GI Tests Launch

This article was originally published in The Gray Sheet

Executive Summary

St. Jude expects to receive a CE mark for a transfemoral 25 millimeter version of its Portico transcatheter aortic valve replacement system during the fourth quarter. NEBA Health launches ADHD test. Exalenz BioScience launches test for H. pylori stomach bacteria.

You may also be interested in...

Regulatory Briefs: FDA Device Reclassifications, Meetings Announcements

FDA proposes class II for nonthermal shortwave therapy devices and updates regulations to reflect class II designation for neuropsychiatric assessment device. Meetings on manufacturing quality, clinical trials and medical countermeasures announced. More regulatory news.

After Slow Start, St. Jude Says Portico TAVI Is Primed To Gain Traction

St. Jude Medical’s Portico transcatheter aortic valve is poised to become more competitive in Europe in 2014 as more sizes become available, executives told investors during the firm’s Feb. 7 annual investor conference. And the firm is talking to FDA about alternative pivotal trial designs.

People Briefs: Execs Named At ImmunID, Natural Molecular Testing, Biolase And Exalenz

ImmunID names president and CEO. Natural Molecular Testing Corp. appoints CFO. Biolase taps VP of marketing. New VP of sales at Exalenz Bioscience.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts